Factors of importance for a successful delivery system for proteins.
Protein pharmaceuticals have matured into an important class of drugs, now comprising one in three novel drugs introduced on the market. However, significant gains are still to be made in reducing the costs of production, ensuring proper pharmacokinetics and efficacy, increasing patient compliance and convenience, and reducing side effects such as immunogenicity. This review summarises these issues and provides recent examples of methods to reduce costs, alter pharmacokinetics and increase patient compliance. It also discusses the increasing interest in understanding immunogenicity in order to prevent failure of the protein drug or serious life-threatening side effects due to autoimmunogenicity.
van de Weert
Marco
M
The Danish University of Pharmaceutical Sciences, Biomacromolecules Group, Department of Pharmaceutics and Analytical Chemistry, Copenhagen, Denmark. mvdw@dfuni.dk
Jorgensen
Lene
L
Horn Moeller
Eva
E
Frokjaer
Sven
S
D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D002626:Chemistry, Pharmaceutical; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D004355:Drug Stability; D004921:Erythropoietin / Q000008:administration & dosage / Q000276:immunology / Q000493:pharmacokinetics; D006801:Humans; D010349:Patient Compliance; D011506:Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000493:pharmacokinetics; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000276:immunology
D011506:Proteins; D011994:Recombinant Proteins; D004921:Erythropoietin